| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Peripheral Neuropathy Center (Dr. Dyck, K.M. Kratz, K.A. Lehman, J.L. Karnes, and Drs. Windebank and Low), the Department of Neurology (Dr. Litchy), the Section of Clinical Epidemiology (Dr. Melton), the Section of Biostatistics (Dr. O'Brien), the Division of Endocrinology, Metabolism and Internal Medicine (Drs. Service, Rizza, and Zimmerman), Mayo Clinic and Mayo Foundation, Rochester, MN, and the Section of Neurology (Dr. Smith) Mayo Clinic Scottsdale, Scottsdale, AZ.
A cross-sectional survey and subsequent longitudinal study among diabetic residents of Rochester, MN- The Rochester Diabetic Neuropathy Study (RDNS)-is population-based and uses quantitative, validated, and unique end points to detect, classify, and stage neuropathy. Nondiabetic persons, drawn from the same population, serve as controls. For patients 10 to 70 years old, the RDNS cohort is representative of diabetics living in Rochester, MN. We assessed reproducibility of tests used to characterize and quantitate severity of neuropathy in 20 diabetic subjects without neuropathy and with varying severities of neuropathy. Using intraclass correlation coefficient (r1) as a measure of test reproducibility, we found high r1 (usually 0.9 or better) with small confidence intervals for the Neurologic Disability Score (NDS); weakness subset of NDS (W-NDS); vibratory and cooling detection thresholds (using computer-assisted sensory examination [CASE] IV); compound muscle action potentials; sensory nerve action potentials; and motor nerve conduction velocities. There was good agreement among three trained observors for NDS and the W-NDS.
Address correspondence and reprint requests to Dr. P.J. Dyck, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Received September 21, 1990. Accepted for publication in final form November 21, 1990.
This article has been cited by other articles:
|
|
 |
|
  S Teelucksingh, M J Ramdass, A Charran, C Mungalsingh, T Seemungal, and V Naraynsingh The slipping slipper sign: a marker of severe peripheral diabetic neuropathy and foot sepsis Postgrad. Med. J., June 1, 2009; 85(1004): 288 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Gibbons, B. M. W. Illigens, N. Wang, and R. Freeman Quantification of sweat gland innervation: A clinical-pathologic correlation Neurology, April 28, 2009; 72(17): 1479 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Dyck, J. E. Norell, H. Tritschler, K. Schuette, R. Samigullin, D. Ziegler, E. J. Bastyr III, W. J. Litchy, and P. C. O'Brien Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity Diabetes Care, October 1, 2007; 30(10): 2619 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. McDermott, R. Sufit, T. Nishida, J. M. Guralnik, L. Ferrucci, L. Tian, K. Liu, J. Tan, W. H. Pearce, J. R. Schneider, et al. Lower extremity nerve function in patients with lower extremity ischemia. Arch Intern Med, October 9, 2006; 166(18): 1986 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Dyck, J. L. Davies, V. M. Clark, W. J. Litchy, P. J. B. Dyck, C. J. Klein, R. A. Rizza, J. M. Pach, R. Klein, T. S. Larson, et al. Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes Diabetes Care, October 1, 2006; 29(10): 2282 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K C Gorson and A H Ropper Additional causes for distal sensory polyneuropathy in diabetic patients. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 354 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Andreassen, J. Jakobsen, and H. Andersen Muscle Weakness: A Progressive Late Complication in Diabetic Distal Symmetric Polyneuropathy Diabetes, March 1, 2006; 55(3): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Mahmud, J. A. Murray, Y. C. Kudva, A. R. Zinsmeister, R. A. Dierkhising, B. D. Lahr, P. J. Dyck, R. A. Kyle, M. El-Youssef, L. J. Burgart, et al. Celiac Disease in Type 1 Diabetes Mellitus in a North American Community: Prevalence, Serologic Screening, and Clinical Features Mayo Clin. Proc., November 1, 2005; 80(11): 1429 - 1434. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Sorenson and A. J. Windebank Incidence of adaptive equipment use in subjects with a remote history of paralytic poliomyelitis Neurology, September 27, 2005; 65(6): 963 - 963. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Dyck, P. C. O'Brien, W. J. Litchy, C. M. Harper, C. J. Klein, and P. J. B. Dyck Monotonicity of Nerve Tests in Diabetes: Subclinical nerve dysfunction precedes diagnosis of polyneuropathy Diabetes Care, September 1, 2005; 28(9): 2192 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Krishnan and M. C. Kiernan Altered nerve excitability properties in established diabetic neuropathy Brain, May 1, 2005; 128(5): 1178 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Sorenson, J. R. Daube, and A. J. Windebank A 15-year follow-up of neuromuscular function in patients with prior poliomyelitis Neurology, March 22, 2005; 64(6): 1070 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kennedy and D. W. Zochodne Experimental Diabetic Neuropathy With Spontaneous Recovery: Is There Irreparable Damage? Diabetes, March 1, 2005; 54(3): 830 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G A Suarez, V M Clark, J E Norell, T E Kottke, M J Callahan, P C O'Brien, P A Low, and P J Dyck Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 240 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Low, L. M. Benrud-Larson, D. M. Sletten, T. L. Opfer-Gehrking, S. D. Weigand, P. C. O'Brien, G. A. Suarez, and P. J. Dyck Autonomic Symptoms and Diabetic Neuropathy: A population-based study Diabetes Care, December 1, 2004; 27(12): 2942 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Zinman, V. Bril, and B. A. Perkins Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments Diabetes Care, July 1, 2004; 27(7): 1674 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Andersen, S. Nielsen, C. E. Mogensen, and J. Jakobsen Muscle Strength in Type 2 Diabetes Diabetes, June 1, 2004; 53(6): 1543 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-P Lefaucheur and A Creange Neurophysiological testing correlates with clinical examination according to fibre type involvement and severity in sensory neuropathy J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 417 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Great Lakes ALS Study Group A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis Neurology, December 9, 2003; 61(11): 1503 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. I. Spielholz, P. J. Dyck, P. C. O'Brien, M. E. Shy, and E. M. Frohman Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, December 9, 2003; 61(11): 1628 - 1630. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al. Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Larsen, H. Sjoholm, K. F. Hanssen, L. Sandvik, T. J. Berg, and K. Dahl-Jorgensen Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years' Duration of Type 1 Diabetes Diabetes Care, August 1, 2003; 26(8): 2400 - 2404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pozzessere, P. Rossi, A. Gabriele, R. Cipriani, A. Morocutti, U. Di Mario, and S. Morano Early Detection of Small-Fiber Neuropathy in Diabetes: A laser-induced pain somatosensory-evoked potentials and pupillometric study Diabetes Care, December 1, 2002; 25(12): 2355 - 2358. [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Gorson, A. H. Ropper, D. H. Weinberg, and R. Weinstein Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy Arch Neurol, May 1, 2002; 59(5): 766 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Kudva, C. Reynolds, T. O'Brien, C. Powell, A. L. Oberg, and T. B. Crotty ""Diabetic Mastopathy,"" or Sclerosing Lymphocytic Lobulitis, Is Strongly Associated With Type 1 Diabetes Diabetes Care, January 1, 2002; 25(1): 121 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J KIMURA Long and short of nerve conduction measures: reproducibility for sequential assessments J. Neurol. Neurosurg. Psychiatry, October 1, 2001; 71(4): 427 - 430. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Perkins, D. Olaleye, B. Zinman, and V. Bril Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic Diabetes Care, February 1, 2001; 24(2): 250 - 256. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. E. Resnick, A. I. Vinik, H. K. Heimovitz, F. L. Brancati, and J. M. Guralnik Age 85+ Years Accelerates Large-Fiber Peripheral Nerve Dysfunction and Diabetes Contributes Even in the Oldest-Old: The Women's Health and Aging Study J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2001; 56(1): 25M - 31. [Abstract] [Full Text]
|
|
|
|
|
|
I. S. J. Merkies, P. I. M. Schmitz, F. G. A. van der Meche, and P. A. van Doorn Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies Neurology, February 22, 2000; 54(4): 943 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. B. Dyck, J. E. Norell, and P. J. Dyck Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy Neurology, December 1, 1999; 53(9): 2113 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Cornblath, V. Chaudhry, K. Carter, D. Lee, M. Seysedadr, M. Miernicki, and T. Joh Total neuropathy score: Validation and reliability study Neurology, November 1, 1999; 53(8): 1660 - 1660. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. C. Pitot, E. A. McElroy Jr., J. M. Reid, A. J. Windebank, J. A. Sloan, C. Erlichman, P. G. Bagniewski, D. L. Walker, J. Rubin, R. M. Goldberg, et al. Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors Clin. Cancer Res., March 1, 1999; 5(3): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. M. Molenaar, M. Vermeulen, M. de Visser, and R. de Haan Impact of neurologic signs and symptoms on functional status in peripheral neuropathies Neurology, January 1, 1999; 52(1): 151 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Backonja, A. Beydoun, K. R. Edwards, S. L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, E. Garofalo, and for the Gabapentin Diabetic Neuropathy Study Group Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial JAMA, December 2, 1998; 280(21): 1831 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. McArthur, E. A. Stocks, P. Hauer, D. R. Cornblath, and J. W. Griffin Epidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency Arch Neurol, December 1, 1998; 55(12): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Omdal, S. Bekkelund, S. Mellgren, and G. Husby C-fibre function in systemic lupus erythematosus Lupus, December 1, 1996; 5(6): 613 - 617. [Abstract] [PDF]
|
|
|
|
|
|
R. Omdal, R. Jorde, S. I. Mellgren, and G. Husby Autonomic Function in Systemic Lupus Erythematosus Lupus, October 1, 1994; 3(5): 413 - 417. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
